Contrast-induced nephropathy (CIN) is a common complication of diagnostic or interventional procedures that may arise from administration of intravascular contrast media. It is defined as an increase in baseline serum creatinine level by ≥25% or an absolute increase of ≥0.5 mg/dL within 48--72 hours after contrast media administration \[[@ref1]\]. CIN has become the third leading cause of hospital-acquired acute kidney injury following surgery and nephrotoxic drug damage, accounting for 11% of observed cases \[[@ref2]\]. The reported incidence of CIN ranges between 5%--50% depending on the previous risk of the investigated patient population \[[@ref3]\]. Pre-existing renal dysfunction and diabetes mellitus (DM) are major patient-related risk factors \[[@ref3]\]. CIN is closely associated with prolonged hospitalization, increased costs, a risk of end-stage renal failure, repeated revascularization, and increased morbidity and mortality in the short- and long-term \[[@ref1], [@ref4], [@ref5]\].

Thiols are organosulfuric compounds that contain carbon-bonded sulfhydryl groups (-SH). They are mostly present in the cytosol and mitochondria \[[@ref6]\], with lower concentrations in plasma. They are composed of human plasma albumin and to a lesser extent by low-molecular-weight thiols such as cysteinylglycine, cysteine (Cys), homocysteine, glutathione, and γ-glutamylcysteine \[[@ref7]\]. Thiols may undergo oxidative reactions that yield various products. One such process is the thiol-disulfide exchange reaction \[[@ref8]\]. When oxidative stress increases, oxidation of Cys residues lead to the reversible formation of mixed disulfides between low-molecular-mass thiols and protein thiol groups. These disulfide bonds can be reduced back to thiol groups, thus maintaining a thiol/disulfide homeostasis \[[@ref9]\]. Therefore, thiols constitute a substantial proportion of the total level of antioxidants and play an important role in the defense mechanisms against radical oxygen species (ROS) \[[@ref10]\].

In recent studies, the thiol-disulfide ratio has been reported to be a novel oxidative stress marker. Although there is a confirmed association of oxidative stress with acute myocardial infarction (AMI) and CIN \[[@ref11]--[@ref14]\], to our knowledge, there are no studies to date that address thiol levels and thiol/disulfide homeostasis in CIN. Therefore, we investigated the role of thiol levels in predicting CIN in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).

MATERIALS AND METHODS {#sec1-2}
=====================

The Local Ethics Committee approved of the study protocol and all participants provided their written informed consents. From November 2016 to September 2017, we prospectively collected in-hospital data from consecutive patients who underwent emergency primary PCI for AMI within 12 hours of the onset of symptoms. The diagnosis of STEMI was established according to contemporary guidelines \[[@ref15]\]. We excluded patients who were on chronic peritoneal or hemodialysis treatment, those who had undergone renal transplantation, or those who had been exposed to a contrast injection within 2 weeks before PCI. Patients with an active infection or chronic inflammatory disease, a significant systemic disease, severe hepatic dysfunction, known malignancy, or major surgery in the previous month were also excluded, as were patients who presented with cardiogenic shock or died during the first 72 hours of their hospital stay or during revascularization. During the study, 302 patients who met the above-mentioned criteria were enrolled. To evaluate the possible relationship between thiol levels and CIN, the study patients were divided into two groups according to the development of CIN, i.e., CIN (+) group and CIN (-) group.

The patients' baseline characteristics were recorded along with their respective in-hospital and follow-up data. In all patients, a detailed medical history was recorded, including the presence and management of hypertension, hypercholesterolemia, diabetes mellitus, family history of coronary artery disease, and smoking status. Patients who had an average blood pressure level of ≥140/90 mmHg or were under antihypertensive medication were considered hypertensive. DM was diagnosed if the patient had fasting glucose levels of ≥126 mg/dl measured twice during the follow-up or was on an antidiabetic prescription before the AMI incident \[[@ref16]\]. Patients who smoked at least one cigarette per day were deemed active smokers.

All primary PCIs were performed via the femoral or radial artery by an experienced interventional cardiologist using the appropriate equipment (Siemens Axiom Artis Z Angiography System, Germany). Non-ionic low osmolality contrast medium (Omnipaque 350 MG/ml; GE Healthcare, Cork, Ireland) was used for these procedures. Total contrast medium volume used during primary PCI was recorded in all patients. All patients were administered 300 mg acetylsalicylic acid (ASA) with a loading dose of 60 mg prasugrel or 180 mg ticagrelor before the procedure. A dose of 70--100 U/kg unfractionated heparin was administered after visualizing the arterial anatomy. The use of bare metal or drug-eluting stents and glycoprotein IIb/IIIa was left to the discretion of the physician. All patients received intravenous hydration with isotonic saline. All patients were transferred to the intensive care unit after the procedure, where treatment was continued with 100 mg ASA and 10 mg prasugrel or 90 mg ticagrelor twice a day. The decision for concurrent use of statins, angiotensin-converting enzyme inhibitors, and beta-blockers was made according to the recommendations in the guidelines. After the coronary intervention, transthoracic echocardiography assessments were performed at the coronary intensive care unit using Vivid 7 (GE Medical System, Horten, Norway) with a 3.5 MHz transducer.

On admission, venous blood samples were obtained before the administration of any medication. Serum creatinine concentration was measured in all patients at admission and at 24 hours, 48 hours, and 72 hours after primary PCI. After the serum samples for thiol were collected, they were centrifuged at 1500 g for 10 minutes and the separated samples were stored in plain tubes at − 80 0C until the analysis. CIN was defined as an increase in serum creatinine concentration by ≥0.5 mg/dL as compared to the admission value or a \>25% relative rise during the first 48--72 hours after the procedure. Serum glucose, creatinine, blood urea nitrogen, alanine-amino transferase, total cholesterol, low-density lipoprotein (calculated with Friedewald Formula: Total cholesterol-(HDLc)-TG/5), high-density lipoprotein, and triglyceride values were measured by an automatic biochemistry analyzer (Roche Diagnostics, Indianapolis, IN, USA). Hematological parameters were measured from citrate-based anticoagulated tubes by the Sysmex K-1000 autoanalyzer (Block Scientific, Bohemia, N.Y., USA) within 30 minutes of sampling.

Thiol/disulfide homeostasis was measured according to the procedure defined by Erel et al. \[[@ref17]\]. Subsequently, the reducible disulfide bonds were reduced to form free functional thiol groups. Sodium borohydride was used as reductant the and unused reductant was extracted with formaldehyde. All thiol groups containing native and reduced bonds were determined after a reaction with 5, 5′-dithiobis-(2-nitrobenzoic) acid. Half of the difference between native and total thiols ensured the dynamic disulfide quantity (−S-S). After determining the amounts of native thiol (−SH) and disulfide (−S-S), the ratio of disulfide to native thiol (−S-S−/−SH) was calculated \[[@ref17]\].

Statistical Analysis {#sec2-1}
--------------------

For baseline characteristics, the Kolmogorov-Smirnov test was used to test the normality of distribution. Quantitative variables with a normal distribution were specified as mean±standard deviation, while variables with non-normal distribution were shown as median (interquartile range) and categorical variables were shown as number and percentage values. For continuous variables with a normal distribution, the Student's t-test was used to compare groups, while the Mann--Whitney U test was used when the distribution was not normal. Categorical variables were compared with Chi-square and Fisher's Exact Chi-square tests. To determine the independent predictors of CIN, parameters with a significance level of 0.1 or less on the univariate analysis were investigated using the univariate and multivariate logistic regression model. The receiver operating characteristics (ROC) curve was used to show the sensitivity and specificity of disulfide/total thiol ratio, which is the optimal cutoff value for predicting CIN. Differences were considered significant at the 2-sided P-value of \<0.05. All statistical analyses were carried out using the SPSS for Windows version 22 (IBM SPSS Inc., Chicago, IL).

RESULTS {#sec1-3}
=======

Demographic, clinical, and laboratory characteristics of the patients are summarized in [Table 1](#T1){ref-type="table"}. The study population consisted of 302 patients with a mean age of 60.2±12.7 years. Of the 302 patients, 130 (43%) were female and 44 (15%) developed CIN. In the CIN group, the baseline creatinine was higher as compared to the non-CIN group. There were no differences in the other parameters between the CIN (+) and CIN (-) groups (p\>0.05) ([Table 2](#T2){ref-type="table"}).

###### 

Baseline clinical, demographic, and laboratory characteristics of the study population

  Age (Med., Mean±SD, Min.-Max.)   59.0 / 60.2±12.7 / 33.0--81.0                 
  -------------------------------- ------------------------------- ------------- -----------
  Gender (Male / Female)           172 (57%) / 130 (43%)                         
  DM, n (%)                        106 (35%)                                     
  HT, n (%)                        131 (43%)                                     
  CAD, n (%)                       87 (29%)                                      
  CABG, n (%)                      32 (11%)                                      
  TIA/Stroke, n (%)                22 (7%)                                       
  AMI localization                                                               
   Anterior / Non-anterior         176 (58%) / 126 (42%)                         
  Access site                                                                    
   Femoral / Radial                184 (61%) / 118 (39%)                         
  Smoking, n (%)                   180 (60%)                                     
                                   Median                          Mean±SD       Min.-Max.
  Glucose (mg/dL)                  124.5                           150.3±81.2    68--533
  Serum creatinine (mg/dL)         1.05                            1.122±0.677   0.63--1.8
  Hemoglobin (g/L)                 13.9                            13.7±1.6      9.6--16.5
  WBC count (x1000/mm^3^)          12.3                            11.5±4.1      5.8--23.7
  Platelet count (x1000/mm^3^)     231                             240.3±87.5    110--626
  Total cholesterol (mg/dL)        191                             188.5±45.6    77--387
  LDL (mg/dL)                      126                             117.4±38.6    51--245
  HDL (mg/dL)                      37.6                            39.7±10.1     16--70
  Triglycerides (mg/dL)            116                             147±92        35--617
  LVEF (%)                         51                              48.1±11       20--64
  Contrast medium volume (mL)      220                             210.1±50.2    90--400

Min.: Minimum; Max.: Maximum; SD: Standard deviation; AMI: Acute myocardial infarction; CABG: Coronary artery bypass graft; CAD: Coronary artery disease; DM: Diabetes mellitus; HDL: High-density lipoprotein; HT: Hypertension; LDL: Low-density lipoprotein; LVEF: Left ventricular ejection fraction; TIA: Transient ischemic attack; WBC: White blood cell.

###### 

Baseline clinical, demographic, and laboratory characteristics of patients with and without contrast-induced nephropathy

                                 CIN (-)     CIN (+)   p                                        
  ------------------------------ ----------- --------- ---- ------ ----------- ---- ---- ------ -----------
  Age                            60.1±12.4                  59.0   60.9±14.1             58.5   0.724^m^
  Sex                                                                                           
   Male                                      155       60                      27   61          0.810^X²^
   Female                                    103       40                      17   39          
  DM                                                                                            
   No                                        170       66                      26   59          0.382^X²^
   Yes                                       88        34                      18   41          
  HT                                                                                            
   No                                        144       56                      27   61          0.492^X²^
   Yes                                       114       44                      17   39          
  Smoking                                                                                       
   No                                        104       40                      18   41          0.675^X²^
   Yes                                       154       60                      26   59          
  CAD                                                                                           
   No                                        185       72                      30   68          0.633^X²^
   Yes                                       73        28                      14   32          
  CABG                                                                                          
   No                                        232       90                      38   86          0.478^X²^
   Yes                                       26        10                      6    14          
  TIA/Stroke                                                                                    
   No                                        237       92                      43   98          0.166^X²^
   Yes                                       21        8                       1    2           
  AMI localization                                                                              
   Anterior                                  148       57                      28   64          0.435^X²^
   Non-anterior                              110       43                      16   36          
  Access site                                                                                   
   Femoral                                   158       61                      26   59          0.511^X²^
   Radial                                    100       39                      18   41          
  Serum creatinine (mg/dL)       1.08±0.32                  1.01   1.13±0.28             1.16   0.036^m^
  Hemoglobin(g/L)                13.8±1.8                   13.8   13.7±1.6              13.5   0.594^m^
  WBC count (x1000/mm^3^)        11.4±3.8                   11.1   12.0±4.7              11.5   0.422^m^
  Platelet count (x1000/mm^3^)   239±78                     231    247±74                243    0.367^m^
  Total cholesterol (mg/dL)      187±45                     190    199±49                199    0.095^m^
  LDL, (mg/dL)                   116±38                     111    126±37                122    0.082^m^
  HDL, (mg/dL)                   39±11                      37     40±10                 39     0.383^m^
  Triglycerides (mg/dL)          142±89                     132    154±95                148    0.082^m^
  LVEF,(%)                       48±10                      50     46±12                 47     0.455^m^
  Contrast medium volume (mL)    210±50                     212    217±60                223    0.105^m^

CIN: Contrast-induced nephropathy; SD: Standard deviation; AMI: Acute myocardial infarction; CABG: Coronary artery bypass graft; CAD: Coronary artery disease; DM: Diabetes mellitus; HDL: High-density lipoprotein; HT: Hypertension; LDL: Low-density lipoprotein; LVEF: Left ventricular ejection fraction; TIA: Transient ischemic attack; WBC: White blood cell. ^m^Mann--Whitney U Test; X²Chi Square (χ^2^) Test.

Native thiol (274.8±84.7 µmol/L vs. 220.8±97.1 µmol/L, p=0.001) and total thiol (305.4±89.7 µmol/L vs. 260.1±102.1 µmol/L, p=0.009) levels were higher in patients in the non-CIN group. Disulfide levels (15.8±6.6 µmol/L vs. 19.6±8.4 µmol/L, p=0.002) and mean disulfide/total thiol ratios (8.4±3.7 vs. 5.9±3.1, p=0.001) were higher in patients with CIN (+) group ([Table 3](#T3){ref-type="table"}). The relationship between the disulfide/total thiol ratio levels with CIN in patients with AMI is shown in [Figure 1](#F1){ref-type="fig"}.

###### 

The level of native thiol, total thiol, disulfide, and disulfide/total thiol ratio between the patients with and without contrast-induced nephropathy (CIN)

                                  CIN (-)      CIN (+)   p                     
  ------------------------------- ------------ --------- ------------- ------- ------------
  Total thiol, (μmol/L)           305.4±89.7   302.8     260.1±102.1   263.3   0.009^m^
  Native thiol (μmol/L)           274.8±84.7   282.5     220.8±97.1    229.1   \<0.001^m^
  Disulfide (μmol/L)              15.8±6.6     15.2      19.6±8.4      18.4    0.002^m^
  Disulfide/Total thiol %, x100   5.9±3.1      5.3       8.4±3.7       8       \<0.001^m^

SD: Standard deviation; CIN: Contrast-induced nephropathy; ^m^Mann--Whitney U Test.

![Relationship between disulfide total thiol ratio levels with contrast-induced nephropathy in patients with acute myocardial infarction.](NCI-6-210-g001){#F1}

The results of the univariate and multivariate regression analysis for CIN are listed in [Table 4](#T4){ref-type="table"}. In the univariate analysis, the initial native thiol, total thiol, disulfide levels, and disulfide/total thiol ratio were found to have prognostic significance in the development of CIN. In the multivariate regression analysis, only the disulfide/total thiol ratio (OR=1.190; 95% CI=1.090--1.300; p=0.001) was significantly and independently associated with CIN.

###### 

Univariate and multivariate logistic regression analysis of contrast-induced nephropathy (CIN)

                                Univariate   Multivariate                                    
  ----------------------------- ------------ -------------- --------- ------- -------------- ---------
  Native thiol                  0.993        0.989--0.997   \<0.001                          
  Total thiol                   0.995        0.991--0.998   0.003                            
  Disulfide                     1.077        1.030--1.126   0.001                            
  Disulfide/Total thiol ratio   1.199        1.098--1.310   \<0.001   1.190   1.090--1.300   \<0.001

CIN: Contrast-induced nephropathy; OR: Odd ratios; CI: Confidence interval.

Finally, the ROC analysis was performed to determine the cutoff value of disulfide/total thiol ratio for predicting CIN. The cutoff value of disulfide/total thiol ratio on admission to predict CIN in patients with STEMI who underwent primary PCI was 7, with a sensitivity of 68.2% and a specificity of 79.8% (AUC=0.740 (0.655--0.825), p\<0.001) ([Fig. 2](#F2){ref-type="fig"}).

![Receiver operator characteristic (ROC) curve analysis showing that at a cut-off of 7, the value of disulfide total thiol ratio exhibited 68.2 sensitivity and 79.8 specificity for predicting contrast-induced nephropathy.](NCI-6-210-g002){#F2}

DISCUSSION {#sec1-4}
==========

The primary finding of this study is that among patients with AMI who underwent primary PCI (in STEMI), the pre-procedural thiol levels that were assessed at admission served as an independent predictor of the development of post-procedural CIN. To our knowledge, this is the first study that investigated thiol/disulfide homeostasis as a novel marker for the relation between oxidative stress and CIN in patients with STEMI. Our findings demonstrated that a high level of disulfide/total thiol was significantly associated with CIN.

Thiols are important antioxidant agents in human beings. The importance of disulfide/thiol homeostasis has been shown in a number of recent studies. Kundi et al. reported that the disulfide/thiol ratio increased in AMI and they asserted that this ratio might be an indicator for detecting acute myocardial damage \[[@ref13]\]. Topuz et al. showed that thiol/disulfide homeostasis could be altered during acute pulmonary thromboembolism and could also be associated with worsened hemodynamic parameters \[[@ref18]\]. They also suggested that this homeostasis may be used as a prognostic marker for hospital mortality. Some studies indicate that low thiol concentrations and an imbalance in the thiol/disulfide ratio may play a pathogenic role in the formation of coronary artery ectasia (CAE), atherosclerosis, and chemotherapy-induced cardiac toxicity \[[@ref19]--[@ref21]\]. In all these studies, the authors hypothesized that oxidative stress might contribute to the main mechanism of pathogenesis. New emerging risk factors such oxidative stress, hs-CRP, N-terminal pro-brain natriuretic peptide, serum uric acid levels, lower bilirubin concentrations, and gamma-glutamyl transferase (GGT) were found to be relevant to CIN development \[[@ref22]--[@ref27]\]. The novel oxidative stress marker in our study, thiol/disulfide ratio, has also been linked to CIN development in patients with acute STEMI undergoing primary PCI.

CIN represents a significant adverse event during administration of contrast medium that leads to worse clinical outcomes despite successful early coronary revascularization. The pathogenesis of CIN is complex and multifactorial and the underlying biological mechanisms have not yet been fully elucidated. Several potential factors have been postulated, such as intrarenal vasoconstriction, reduced renal blood flow, medullary hypoxia, oxidative stress, inflammation, thrombosis, endothelial dysfunction, generation of reactive oxygen species (ROS), and direct tubular epithelial cell injury by contrast media \[[@ref6], [@ref7], [@ref28]\]. In certain trials, the pathophysiology of CIN appears to be based on the formation of ROS and tubular cell toxicity \[[@ref29], [@ref30]\]. The plasma thiol/disulfide homeostasis shows a synergistic effect with the contrast media and increases acute kidney injury incidence by increasing ROS levels. Common findings in recent studies on thiol/disulfide levels include decreased native thiol level, increased disulfide level, and increased disulfide/total thiol ratio due to excess oxidative stress \[[@ref13], [@ref14], [@ref18]\]. Consistent with previous studies, we found that patients in the CIN (+) group had lower native thiol but a higher disulfide level and disulfide/total thiol ratio as compared to the CIN (-) group.

CIN is closely associated with prolonged hospitalization, increased costs, and increased short- and long-term morbidity and mortality \[[@ref1]\]. Various strategies are hence being employed to prevent the incidence of CIN. Recently, increasing evidence has suggested that statins may, aside from their lipid-lowering effect, also play a protective role for the kidneys in the prevention of CIN due to their pleiotropic effects that include anti-inflammatory and antioxidant actions and the enhancement of endothelial nitric oxide production \[[@ref31], [@ref32]\]. In other studies involving N-acetylcysteine (NAC), it was demonstrated that the inhibition of reactive oxygen species (ROS) may represent a key mechanism of the nephroprotective effect of NAC \[[@ref33], [@ref34]\]. Based on these findings, we can speculate a relationship between thiol/disulfide homeostasis and CIN.

We suggest that the lower native thiol and higher disulfide level in AMI patients are probably due to an increase in thiol oxidation due to the excess oxidative status during AMI. During the acute phase in AMI, the oxidative response may affect the baseline cardiorenal reserves of the patients. Addition of thiol levels to the current risk models derived from clinical, angiographic, and laboratory-based variables and to the previously validated Mehran risk score \[[@ref35]\] may result in significant improvement in the prediction of CIN. This suggests that measurement of thiols improves the evaluation of risk for CIN in patients with STEMI who are undergoing primary PCI.

Study Limitations {#sec2-2}
-----------------

Our study had several limitations. First of all, it included a relatively small number of CIN patients who were admitted to a single center. Secondly, blood samples were obtained at the time of admission, and we did not observe the serial changes in thiols concentration after primary PCI. Thirdly, several novel renal biomarkers, including neutrophil gelatinase-associated lipocalin, cystatin C, urinary Kim-1, and interleukin 18, were not measured during the study \[[@ref36], [@ref37]\]. Fourthly, because all patients in the present study underwent emergency PCI, the total fluid volume and net fluid balance were not quantified. Moreover, thiols are nonspecific inflammatory and oxidative stress biomarkers that are influenced by cardiac and extra-cardiac conditions. The study group included some patients with diabetes mellitus and potential renal dysfunction, which was another limitation of this study. Finally, the deterioration of renal function after primary PCI may have been caused by multiple other contributing factors, including hemodynamic alterations, neurohormonal activation, and administration of nephrotoxic drugs.

CONCLUSION {#sec1-5}
==========

Our results suggest that thiol/disulfide homeostasis could be a good biochemical risk marker for CIN in STEMI patients who have undergone primary PCI. Considering its clinical significance, thiol/disulfide homeostasis may help in identifying high-risk candidates of CIN in AMI. We believe that larger prospective studies are needed in the future to confirm the pathophysiological role of thiol/disulfide homeostasis in CIN and to provide valuable insights into the relevant literature.
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